OPEN END TURBO LONG - BOSTON SCIENTIFIC | Market Closed - Börse Stuttgart 03:56:43 2024-06-27 pm EDT | ||
| 3.16 EUR | -0.94% |
|
| 1 month | +2.93% | ||
| 3 months | +29.51% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BOSTON SCIENTIFIC CORPORATION
More news
| Date | Price | Change |
|---|---|---|
| 24-06-27 | 3.16 | -0.94% |
| 24-06-26 | 3.19 | -0.31% |
| 24-06-25 | 3.2 | +2.24% |
| 24-06-24 | 3.13 | -3.40% |
| 24-06-21 | 3.24 | +2.53% |
Delayed Quote Börse Stuttgart
Last update June 27, 2024 at 03:56 pm EDT
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | BOSTON SCIENTIFIC CORPORATION |
| Issuer | Morgan Stanley |
| WKN | MD5NY9 |
| ISIN | DE000MD5NY95 |
| Date issued | 2022-06-28 |
| Strike | 43.23 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.21 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.24 € |
|---|---|
| Lowest since issue | 0.028 € |
Company Profile
Boston Scientific Corporation specializes in the design, manufacturing and marketing of medical equipment and materials. Net sales break down by area of application as follows:
- cardiovascular (60.6%): products used in cardiology surgeries (27.4% of net sales), cardiac rhythm management (25.2%), peripheral surgeries (23.9%), electrophysiology tests (9.1%) and other (14.4%);
- endodontic surgery (37.4%): equipment used in endoscopy (45.8% of net sales), urology (36.2%) and other (18%) ;
- neuromodulation (2%).
The United States account for 59.2% of net sales.
Sector
-
Ratings for Boston Scientific Corporation
Trading Rating
Investor Rating
ESG Refinitiv
A-
Consensus: Boston Scientific Corporation
Sell
Buy
Mean consensus
BUY
Number of Analysts
32
Last Close Price
77
USD
Average target price
82.35
USD
Spread / Average Target
+6.95%
- Stock Market
- Certificates
- Certificat
